Actualités

Gut4 j
Targeting Treg–fibroblast interaction to enhance immunotherapy in steatotic liver disease-related hepatocellular carcinoma
Background Steatotic liver disease-related hepatocellular carcinoma (SLD-HCC), a rising global challenge, is characterised by ...
Gut3 j
Rethinking ‘Inactive Chronic Hepatitis B’: should we treat patients with high HBsAg levels?
We read with great interest the recent article by Tseng et al evaluating hepatitis B surface antigen (HBsAg) levels as a ...
Gut5 j
New look on oats in coeliac disease
The suitability and tolerability of oats has been a long-standing controversy in the management of coeliac disease (CD). In ...
gut.bmj1 mois
Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease
15 Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore Background Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over 30% of the general ...
gut.bmj10 j
Non-invasive tests of fibrosis in the management of MASLD: revolutionising diagnosis, progression and regression monitoring
4 State Key Laboratory of Digestive Disease, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China With the recent conditional approval of resmetirom by the US Food and ...
gut.bmj8 j
Endoscopic intermuscular dissection for rectal cancer: are we ready to skip surgery?
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...
gut.bmj16 j
Therapeutic inhibition of HBsAg and HBV cccDNA through a novel phased combination treatment: glycine and interferon-α
Background The elimination of HBV covalently closed circular DNA (cccDNA) remains a critical hurdle for chronic hepatitis B (CHB) management. Objective In this investigation, we examined the efficacy ...